|

Safer Surgery for Mesothelioma Patients: Promising Strategies Revealed in Recent Study

Safer Surgery for Mesothelioma Patients: Promising Strategies Revealed in Recent Study

Researchers from the University of Pennsylvania tested four strategies to make mesothelioma surgery safer for patients.

Enhancing Mesothelioma Surgery Safety

Mesothelioma is a rare type of cancer caused by asbestos. It is found in the lining of organs in the body. The most common locations for mesothelioma are in the lungs and abdomen. In this study, the patients had mesothelioma in the lungs.

The treatment plan for mesothelioma usually combines multiple therapies. The conventional treatment strategy is surgery, chemotherapy, and radiation.

One type of surgery for mesothelioma is called pleurectomy and decortication (P/D). This surgery is performed by a thoracic surgeon. The surgeon first removes as much of the diseased lung membrane as possible (pleurectomy). The second step is to scrape any remaining cancer away from the surface of the lungs (decortication).

While P/D can be effective in removing cancer from the lungs, it also comes with risks and side effects. These can include pneumonia, deep vein thrombosis, and sepsis.

The researchers in this study tested four changes to the P/D procedures that might reduce these dangerous side effects:

  • creation of a tracheostomy, or tube in the throat,
  • insertion of a gastrostomy tube, or tube in the stomach, two weeks before surgery,
  • insertion of a jejunostomy tube, or tube in the small intestine, two weeks before surgery, and
  • starting medicine to prevent blood clots.

The researchers hoped that one or more of these strategies would improve the safety of P/D for mesothelioma patients.

Study Shows How to Minimize Surgery Side Effects

To test these strategies, the researchers looked at 55 mesothelioma patients who received P/D between 2015 and 2022.

They found that patients with a tracheostomy were less likely to be infected with pneumonia. Patients who were given medicine to prevent blood clots were less likely to be affected by deep vein thrombosis. And patients with a gastronomy tube were less likely to experience sepsis.

The researchers were excited by these results and encourage more studies on larger groups of patients to gather more information about reducing side effects after P/D.

Source

Bou-Samra P, Chang A, Zhang K, et al. Strategies to reduce morbidity following pleurectomy and decortication for malignant pleural mesothelioma [published online ahead of print, 2023 Aug 13]. Thorac Cancer. 2023;10.1111/1759-7714.15067. doi:10.1111/1759-7714.15067. https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.15067

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…